About the Burkitt Lymphoma Session
Burkitt lymphoma presents a formidable challenge in the realm of cancer research. This rare and aggressive non-Hodgkin lymphoma variant demands keen scientific scrutiny due to its swift proliferation within the lymphatic system, often leading to noticeable swellings in various body regions. Scientists are meticulously probing its genetic and environmental underpinnings, striving to unravel its intricate origins. Breakthroughs in genomic sequencing have unveiled specific genetic aberrations associated with Burkitt lymphoma, paving the path for targeted therapeutic interventions. Immunotherapeutic strategies, including monoclonal antibodies and CAR-T cell therapy, hold significant promise in augmenting treatment efficacy. Moreover, ongoing clinical trials exploring innovative combination therapies and emerging agents aim to revolutionize patient care and survival outcomes. Amidst these endeavors, the quest for deeper insights into Burkitt lymphoma persists, igniting optimism for transformative breakthroughs in its management.
Topics Covered in Burkitt Lymphoma
MYC Translocation
Endemic & Sporadic Forms
EBV & Malaria Cofactors
HIV-Associated Disease
Tumor Lysis Syndrome
Dose-Intensive Chemotherapy
Related Scientific Sessions at CIOC 2027
Why Attend the Burkitt Lymphoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Burkitt Lymphoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Burkitt Lymphoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Burkitt Lymphoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Burkitt Lymphoma Conference 2027 — FAQs
What is the Burkitt Lymphoma track at CIOC 2027?
The Burkitt Lymphoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Burkitt Lymphoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Burkitt Lymphoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Burkitt Lymphoma are all welcome — whether presenting or attending.
Can I present my research in the Burkitt Lymphoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Burkitt Lymphoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Burkitt Lymphoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.